PARSHALL B LYNNE

SEC source: 0001061983-21-000250 · edgardoc.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000250 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000250 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000240 · edgardoc.xml · derivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,798

Underlying: Common Stock · 1,999 shares

Expires 2023-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000240 · edgardoc.xml · derivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,333 shares

Expires 2023-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000240 · edgardoc.xml · nonDerivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000240 · edgardoc.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000240 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0001061983-21-000240 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on August 17, 2021.

SEC source: 0000874015-21-000139 · edgardoc.xml · derivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,529

Underlying: Common Stock · 1,778 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-21-000139 · edgardoc.xml · derivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,307

Underlying: Common Stock · 889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-21-000139 · edgardoc.xml · derivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,196

Underlying: Common Stock · 5,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-21-000139 · edgardoc.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,378

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

SEC source: 0000874015-21-000139 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

SEC source: 0000874015-21-000139 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

SEC source: 0000874015-21-000117 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,529

Underlying: Common Stock · 5,333 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Grant of July 1, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2021.

F3 · derivative.expiration_date: Grant of July 1, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2021.

SEC source: 0000874015-21-000117 · edgardoc.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2031-06-30

F1 · derivative.exercise_date: Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2021.

F1 · derivative.expiration_date: Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2021.

SEC source: 0001061983-21-000144 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-05-12

F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022.

SEC source: 0001061983-21-000144 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022.

SEC source: 0000874015-21-000031 · edgar.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,754

Underlying: Common Stock · 10,655 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000031 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,378

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000031 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-20-000174 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,464

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

SEC source: 0000874015-20-000154 · edgar.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000154 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,464

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85-$50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000154 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

SEC source: 0000874015-20-000146 · edgar.xml · derivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,590

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,464

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4.

SEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,174

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

SEC source: 0000874015-20-000146 · edgar.xml · derivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,300

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,464

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020.

SEC source: 0001209191-20-054604 · doc4.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,400 shares

Expires 2030-04-12

F1 · derivative.exercise_date: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

SEC source: 0001061983-20-000167 · edgardoc.xml · derivative · entry 12

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,375 shares

Expires 2026-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · derivative · entry 11

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2026-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · derivative · entry 10

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,936 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · derivative · entry 9

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2025-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 8

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 7

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0001061983-20-000167 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 15, 2020.

SEC source: 0000874015-20-000103 · edgar.xml · derivative · entry 4

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,777

Underlying: Common Stock · 889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-20-000103 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,464

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-20-000103 · edgar.xml · derivative · entry 6

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-30

F5 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020.

F5 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020.

SEC source: 0000874015-20-000103 · edgar.xml · derivative · entry 5

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,333

Underlying: Common Stock · 5,333 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020.

F4 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020.

SEC source: 0000874015-20-000103 · edgar.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,332

Underlying: Common Stock · 1,778 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.